Interview With Abner Kurtin, CEO of Ascend Wellness Holdings
We discuss what drove the strong second quarter, what happened with their deal for MedMen's New York assets and opportunities for federal progress. The conversation concludes with Abner sharing what factors he would consider when building a cannabis-investment portfolio.
Evaluating Advisor Shares Cannabis ETFs
AdvisorShares is among the most experienced cannabis-ETF managers, and in this article, we’ll review their offerings and discuss why now may be the right time to begin accumulating cannabis stocks.
Green Giants June 2022 Newletter
June marked the end of a brutal first half of the year. The S&P 500 finished down -20.6%, its worst start since 1970 and the MSCI World Index return of -20.9% was the worst first-half in its history. Inflation and slowing growth are taking their toll on all risk assets.
An Introduction To Terrascend: A Wild Opportunity
TerrAscend is best known for its outstanding senior-leadership team headed by Executive Chairman Jason Wild along with President & COO Ziad Ghanem. This, coupled with their deep footprint in fast-growing states makes TerrAscend one of the most compelling cannabis companies.
Green Giants May 2022 Newsletter
During May broad US indexes finished about flat and cannabis stocks posted another negative month. The US cannabis markets have lost money in 14/15 months and are in the midst of a 75% drawdown. There is no way to sugarcoat it: this is a painful period.
Ayr Rises on New Jersey News and Is Still Cheap
Ayr remains the cheapest MSO on an enterprise value/sales and enterprise value/adjusted-EBIDTA basis. This, coupled with the potential for a strong second half of the year makes it an attractive opportunity.
Why I'm Back In Ayr Wellness, For Now...
Among its peer group, AYR has the fastest-growing sales, and is the cheapest according to two valuation metrics. This is compelling, but sometimes it takes a catalyst to reverse sentiment and renew interest in a stock. Thankfully, one is on the horizon.
Green Giants April 2022 Newsletter
The S&P 500 is off to its worst start since 1939, and the NASDAQ notched its worst opening quarter since launching in 1971. For cannabis stocks, it was the worst month since COVID-lows of March 2020.
Interview with Khiron CEO Alvaro Torres: Medical Cannabis In Latin America
My favorite segment was talking about how they are transitioning from treating chronic pain with cannabis versus opioids. This hits home with me, as my dad is having great results using cannabis for his Chronic Regional Pain Syndrome. Khiron is seeing similar outcomes.
Interview with Weedmaps CEO Chris Beals: Amazon Meets Shopify Meets Cannabis
For investors seeking cannabis exposure in a NASDAQ-listed stock, Weedmaps is an excellent option.
